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Neurotrophins, activating the PI3K/Akt signaling pathway,
control neuronal survival and plasticity. Alterations in NGF,
BDNF, IGF-1, or insulin signaling are implicated in the patho-
genesis of Alzheimer disease.We have previously characterized
a bigenic PS1APP transgenic mouse displaying early hip-
pocampal A deposition (3 to 4 months) but late (17 to 18
months) neurodegeneration of pyramidal cells, paralleled to the
accumulation of soluble A oligomers. We hypothesized that
PI3K/Akt/GSK-3 signaling pathway could be involved in this
apparent age-dependent neuroprotective/neurodegenerative
status. In fact, our data demonstrated that, as compared with
age-matched nontransgenic controls, the Ser-9 phosphoryla-
tion of GSK-3 was increased in the 6-month PS1APP hip-
pocampus, whereas in aged PS1APP animals (18 months),
GSK-3 phosphorylation levels displayed a marked decrease.
UsingN2a and primary neuronal cell cultures, we demonstrated
that soluble amyloid precursor protein- (sAPP), the predom-
inant APP-derived fragment in young PS1APP mice, acting
through IGF-1 and/or insulin receptors, activated the PI3K/Akt
pathway, phosphorylated the GSK-3 activity, and in conse-
quence, exerted a neuroprotective action. On the contrary, sev-
eral oligomeric A forms, present in the soluble fractions of
aged PS1APPmice, inhibited the induced phosphorylation of
Akt/GSK-3 anddecreased theneuronal survival. Furthermore,
synthetic A oligomers blocked the effectmediated by different
neurotrophins (NGF, BDNF, insulin, and IGF-1) and sAPP,
displaying high selectivity for NGF. In conclusion, the age-de-
pendent appearance of APP-derived soluble factors modulated
the PI3K/Akt/GSK-3 signaling pathway through the major
neurotrophin receptors. sAPP stimulated and A oligomers
blocked the prosurvival signaling. Our data might provide
insights into the selective vulnerability of specific neuronal
groups in Alzheimer disease.
The molecular mechanisms underlying the selective neuro-
degeneration inAlzheimer disease (AD)5 remain unclear. Amy-
loid- (A) peptides, proteolytically excised from the amyloid
precursor protein (APP), are considered the primary patholog-
ical agents in AD. However, their precise modes of action, toxic
conformational forms, and molecular targets are still contro-
versial (for review see Ref. 1). Transgenic mouse models, over-
expressing mutated forms of human APP, are widely used to
study AD pathogenesis. These models develop extensive A
deposition in the disease-vulnerable brain regions (such as hip-
pocampus); however, neurons are well protected until late ages.
The factors and pathways maintaining neuronal integrity at
young/middle ages in theseADmodels and those inducing neu-
rodegeneration in the aged animals remains to be defined.
NGF, BDNF, IGF-1, and insulin are trophic factors critical
for neuronal survival and plasticity, underlying memory, and
learning (2–4) and could be implicated in AD development.
Changes in growth factor expression and distribution, as well in
their receptors (TrkA, TrkB, p75NTR, IGF-1R, and insulin-R),
have been reported inADandADmodels (5). In fact, it has been
suggested that the imbalance between NGF, its precursor pro-
NGF, and the high (TrkA) and low (p75NTR) affinity NGF
receptors seems to be a crucial factor underlying neurodegen-
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eration in AD (6, 7). Furthermore, defects in IGF-1R and insu-
lin-R signaling are associated with amyloid plaque and neuro-
fibrillary tangle pathology (8). In this sense, it has been reported
that insulin resistance, central to type II diabetes, was impli-
cated in the pathogenesis of AD. Alterations in IGF-1R, insu-
lin-R, and IRS-1/2 inADare implicated in insulin resistance (9).
In fact, AD has been considered as a brain-specific “type III
diabetes” (10, 11). Insulin administration facilitates memory in
patientswithAD (12), and IGF-1 is protective against the devel-
opment of A pathology (13). However, themechanisms impli-
cated in the A-mediated insulin resistance are still unknown.
Trophic factors promote neuronal survival largely through
the PI3K/Akt signaling pathway (14). After activation, phos-
pho-Akt phosphorylates and inhibits the glycogen synthase
kinase-3 (GSK-3). The “GSK3 hypothesis of AD” (15)
proposed that the overactivity of GSK-3 accounts for several
features of this pathology such as memory impairment, Tau
phosphorylation, increased amyloid production,microglia-me-
diated inflammation, and neuronal death. In fact, GSK-3
mediates the hyper-phosphorylation of Tau (16) and produces
impairments in learning and memory by preventing the induc-
tion of long term potentiation (17). GSK-3 activity also is crit-
ical for inflammatory cell differentiation, migration, and secre-
tion of pro-inflammatory cytokines (18), so it could potentially
heighten microglia-mediated inflammatory responses in the
local vicinity of A plaques. Moreover, GSK-3modulates key
steps of themajor apoptotic signaling pathways (themitochon-
drial intrinsic apoptotic and the death receptor-mediated
extrinsic apoptotic pathways) (19).
Increasing evidence suggests that the PI3K/Akt/GSK-3 sig-
naling pathway is directly impacted by A exposure and is
altered in AD brains. In this sense, soluble (or diffusible) A
oligomers (putative toxic agents in AD) (20, 21) have been asso-
ciated with Tau hyperphosphorylation (22), inhibition of long
term potentiation, disruption of memory, loss of dendritic
spine density (23), neuronal death (24, 25), and neurotoxic
inflammatory response (26). Furthermore, A oligomers have
been shown to modulate the expression and density of insulin
receptors through the modulation of the PI3K/Akt pathway
(27), and alterations in the levels of phosphorylated Akt sub-
strates have been reported in AD patients (28).
In this study, we have addressed the possible age-dependent
variations in the GSK-3 phosphorylation in our PS1APP tg
model. This model developed early A (3 to 4 months) plaques
(29–31) but late (17 to 18 months) hippocampal neuronal
degeneration, paralleled with the accumulation of soluble A
oligomers (26). Themolecular changes that drive to this appar-
ent age-dependent protective/degenerative neuronal condition
are still unresolved. We hypothesized that the PI3K/Akt/
GSK-3 signaling pathway could be involved. Using in vivo and
in vitro assays, we report that natural and synthetic A oligo-
mers, acting through growth factor receptors, inhibit the pro-
survival signaling PI3K/Akt/GSK-3. Moreover, at early ages,
despite the A plaques, soluble APP, acting through IGF-1
and insulin receptors, activated the prosurvival PI3K-Akt-
GSK-3 pathway that might account for the lack of neurode-
generation in most transgenic models at these ages.
EXPERIMENTAL PROCEDURES
Antibodies—A11 and 6E10 antibodies were purchased from
Invitrogen and Signet Laboratories, respectively. Anti-soluble
APP was provided by Immuno-Biological Laboratories. Anti-
phospho-GSK-3 (Ser-9); phospho-Akt (Ser-473); phospho-
Akt (Thr-308); phospho-IGF1 receptor  (Tyr-1135/1136);
pTrkA-B (TrkA, Tyr-674/675; TrkB, Tyr-706/707) were from
Cell Signaling Laboratory. Anti-phospho-insulin receptor
(Tyr-1150/1151) was purchased from Millipore. Monoclonal
anti-human PHF-Tau (Clone AT100) was purchased from
Innogenetics. Anti-phospho- and total -catenin antibodies
were from Cell Signaling Laboratory and Abcam, respectively.
Anti--actin was purchased from Sigma.
Transgenic Mice—The generation and initial characteriza-
tion of the PS1M146LAPP751sl (PS1APP) tg mice has been
reported previously (29). This double tg mice (C57BL/6 back-
ground) were generated by crossing homozygotic PS1M146L
mice with heterozygotic Thy1-APP751SL mice (all tg mice
were provided by Transgenic Alliance, IFFA Credo, Lyon,
France). Mice represented F10–F15 offspring of heterozygous
tg mice. Only male mice were used in this work. Age-matched
PS1M146L and nontransgenic (WT) male mice of the same
genetic background (C57BL/6) were used as controls.
For glucose determination, the anesthetized (sodium pento-
barbital; 60 mg/kg) animals were bled (50 l) from the tail. The
glucose levels were similar between ages and genotypes (inmM:
6.4 1.4, 5.4 1.2; 7.3 1.2 and 6.5 1.4, n 7, for 6 or 18
months, WT and PS1APP, respectively). After bleeding, the
mice were killed by decapitation, and both hippocampi were
dissected, frozen in liquidN2, and stored at80 °Cuntil use. All
animal experiments were performed in accordance with the
guidelines of the Committee of Animal Research of the Univer-
sity of Seville (Spain) and the European Union Regulations.
RNA and Total Protein Extraction—Total RNA was ex-
tracted using the TripureTM isolation reagent (Roche Applied
Science) as described previously (30, 31).
The contaminating DNA in the RNA samples was removed
by incubation with DNase (Sigma) and confirmed by PCR anal-
ysis of total RNA samples prior to reverse transcription (RT).
After isolation, the integrity of the RNA samples was assessed
by agarose gel electrophoresis. The yield of total RNA was
determined by measuring the absorbance (260/280 nm) of eth-
anol-precipitated aliquots of the samples. The recovery of RNA
was comparable in all groups (1.2–1.5 g/mg of tissue). The
protein pellets, obtained using the TripureTM isolation reagent,
were resuspended in 4% SDS and 8 M urea in 40 mM Tris-HCl,
pH 7.4, and rotated overnight at room temperature (30, 31).
Retrotranscription and Real Time RT-PCR—The retrotrans-
cription (RT) was done using random hexamers, and 3 g of
total RNA as template and high capacity cDNA archive kit
(Applied Biosystems) following the manufacturer recommen-
dations (30, 31). For real time RT-PCR, each specific gene
product was amplified using commercial TaqManTM probes,
following the instructions of the manufactured (Applied Bio-
systems), using an ABI Prism 7000 sequence detector (Applied
Biosystems). For each assay, a standard curve was first con-
structed, using increasing amounts of cDNA. In all cases, the
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slope of the curves indicated optimal PCR conditions (slope
3.2–3.4). The cDNA levels of the different mice were deter-
mined using two different housekeepers (i.e.GAPDHand-ac-
tin). The amplification of the housekeepers was done in parallel
with the gene to be analyzed. Similar results were obtained
using both housekeepers. Thus, the results were normalized
using only the GAPDH expression.
Independently of the gene analyzed, the results were always
expressed using the comparativeCtmethod, following Bulletin
2 fromApplied Biosystems. As a control condition, we selected
6-month-old WT mice. In consequence, the expression of all
tested genes, for all ages andmouse types, was referenced to the
expression levels observed in 6-month-old WT mice.
A42 Peptide Preparation—To prepare the A42 peptides,
we allowed synthetic lyophilized A(1–42) peptide (human
sequence, Anaspec) to equilibrate, at 20–23 °C, for 30 min
before it was resuspended and diluted to 1 mM in hexafluoro-
2-propanol. After evaporation, peptide films were dried in a
Speed vacuum and stored at40 °C. Peptide films were resus-
pended to 5 mM in dimethyl sulfoxide (DMSO) for 10 min. To
form the ADDLs (32), we diluted the 5 mM DMSO solution to
100 M in cold PBS, vortexed for 30 s, and incubated overnight
at 4 °C. Before use, the A/PBS solution was further diluted in
culture media. The presence of ADDLs was tested by Western
blots using 6E10 (data not shown).
To form the monomers, immediately before use, we diluted
the 5mMDMSOsolution in PBS (to a final concentration of 100
M), following by ultrafiltration through 5-kDa cutoff device
(Vivaspin 2, Sartorius Biolab Products). The presence of the
monomeric A42 peptide (4.5 kDa) was verified by Western
blots (data not shown).
Soluble Protein Extraction (Soluble Fractions) and Immu-
noprecipitation—The soluble fractions were obtained by ultra-
centrifugation of the homogenates as described previously (26,
33). Briefly, tissue samples were homogenized (using a Dounce
homogenizer) in cold isotonic buffer (0.32 M sucrose, 1 mM
EDTA, 1 mM EGTA, 20 mM Tris-HCl, pH 7.5, containing a
mixture of protease and phosphatase inhibitors, Sigma) and
ultracentrifuged (OptimaTMMAXPreparativeUltracentrifuge,
Beckman Coulter) at 120,000  g, 4 °C, during 60 min. Imme-
diately after centrifugation, the samples were aliquoted and
stored at 81 °C until use. The protein content in the soluble
fractions was determined by Lowry. To diminish the potential
inter-individual variability, the S1 fractions from four different
mice, for each age and genotype, were pooled.
For immunoprecipitation experiments, 50g of soluble pro-
teins were incubated, overnight at 4 °C with continuous shak-
ing, with A11 antibody, previously adsorbed to protein G-Sep-
harose or protein A-Sepharose beads (Sigma) (2 g of purified
antibody/20 g of protein G- or A-Sepharose) in the presence
of protease inhibitors (RocheApplied Science) in a final volume
of 500l of TBS. Immunobeads were isolated by centrifugation
and washed three times in cold TBS. Finally, the immunopre-
cipitated proteins were eluted using 20 l of Laemmli’s buffer
and analyzed by Western blots.
For in vitro experiments, the soluble fractions from the dif-
ferent mice and ages were thawed immediately before use,
diluted with DMEM (without FBS), sterilized by filtration
(through 0.22-m filters, Millipore), and added to cell cultures.
For each experiment, duplicate wells were stimulated under the
same experimental conditions.
The immunodepletion experiments were done basically as
described previously (26, 34). Briefly, 50 g of protein from
soluble fractions from 6- and 18-month-old PS1APP mice
(n  3/age) were subjected to three sequential incubations
(8–12 h at 4 °C) with either 6E10 (5g) proteinG-Sepharose or
A11 (5 g) protein A-Sepharose immunocomplexes. After
immunodepletion, the soluble fractions were used for in vitro
stimulation (see below). As control, the different soluble frac-
tions were sequentially incubated with either protein G-Sep-
harose or protein A-Sepharose and tested, in parallel experi-
ments, with the immunodepleted samples.
Western Blot and Dot Blot—Western blots were performed
as described previously (34). Briefly, 10–20 g of protein from
the different samples were loaded on 16% SDS-Tris-Tricine-
PAGE and transferred to nitrocellulose (Hybond-C Extra,
Amersham Biosciences). Alternatively, the immunoprecipi-
tated samples were electrophoresed on 12% SDS-Tris glycine.
After blocking, the membranes were incubated overnight, at
4 °C, with the appropriate antibody. Themembranes were then
incubated with anti-mouse horseradish peroxidase-conjugated
secondary antibody (Dako, Denmark) at a dilution of 1:8000.
The blotswere developed using the ECL-plus detectionmethod
(Amersham Biosciences).
Dot blots were done as described previously (26, 34). Oneg
of protein from the different soluble fractions were directly
applied to dry nitrocellulose in a final volume of 2l. Blots were
air-dried, blocked for 1 h, and incubated overnight at 4 °C, with
either Nu-1 (courtesy of Dr. W. Klein; 1 g/ml) or A11 (1:5000
dilution, BIOSOURCE) antibodies. After the incubation, the
blots were washed and visualized as described above.
For quantification, the scanned (Epson 3200) images were
analyzed using the PCBAS program. In each experiment, the
intensity of bands from WT mice and/or experimental condi-
tionswere averaged and considered as 1 relative unit. Datawere
always normalized by the specific signal observed in 6-month-
old WT group or negative control for “in vitro” experiments.
Tissue Preparation—After deep anesthesia with sodiumpen-
tobarbital (60 mg/kg), 6- and 18-month-old control (WT) and
PS1APP tg male mice (n  4/age/genotype) were perfused
transcardially with 0.1 M phosphate-buffered saline (PBS), pH
7.4, followed by 4% paraformaldehyde, 75 mM lysine, 10 mM
sodium metaperiodate in 0.1 M phosphate buffer (PB), pH 7.4.
Brains were then removed, post-fixed overnight in the same
fixative at 4 °C, cryoprotected in 30% sucrose, sectioned at 40
mthickness in the coronal plane on a freezingmicrotome, and
serially collected in wells containing cold PBS and 0.02%
sodium azide. All animal experiments were approved by the
Committee of Animal Use for Research of the Malaga Univer-
sity (Spain) and the European Union Regulations.
Immunohistochemistry—Coronal free-floating brain sec-
tions (40 m thick) from 6-and 18 month-old control (WT)
and PS1APP mice were processed simultaneously for
phospho-GSK-3 immunolabeling in the same solutions and
conditions to prevent processing variables. Sections were
first treated with 3% H2O2, 3% methanol in PBS and with
AOligomers Reverse Neuroprotective Effect of sAPP
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avidin-biotin blocking kit (Vector Laboratories, Burlingame,
CA) and then incubated overnight at room temperature with
rabbit anti-GSK-3 (phospho-Ser-9) antibody (dilution
1:100, Abcam ab30619).
The tissue-bound primary antibodywas detected by incubat-
ing with the corresponding biotinylated secondary antibody
(1:500 dilution, Vector Laboratories) and then followed by
streptavidin-conjugated peroxidase (Sigma) diluted 1:2000.
The reaction was visualized with 0.05% 3,3-diaminobenzidine
tetrahydrochloride (Sigma), 0.03% nickel ammonium sulfate,
and 0.01% hydrogen peroxide in PBS. Sections were then
mounted on gelatin-coated slides, air-dried, dehydrated in
graded ethanols, cleared in xylene, and coverslipped with DPX
(BDH) mounting medium. Specificity of the immune reaction
was controlled by omitting the primary antiserum.
N2a and Primary Neuronal Cultures—N2a cells were plated
at 25,000 cells/cm2 and cultured in high glucose DMEM/
OptiMEM (50–50%) supplemented with 2 mM glutamine and
5% fetal bovine serum (PPA Co.) in the presence of penicillin
and streptomycin (100 units/ml and 0.01 mg/ml, respectively).
For stimulation experiments, the medium was change to high
glucose DMEM and serum-deprived for 12 h. The cells were
stimulated using 5% fetal bovine serum, 100 nM IGF-1 (Sigma),
100 nM insulin (Sigma), 10 nMNGF- (Sigma), or 25 nM sAPP
(Sigma) in the presence or absence of ADDLs (ranging from
0.01 to 2 M; estimated from the initial A42 concentration
used for oligomerization; we are aware that the ADDL concen-
tration could be underestimated). After stimulation, the pro-
teins were isolated and analyzed as described above.
Primary neuronal cultures were done essentially as described
previously (27). Briefly, embryonic E18–20 or postnatal P1
brains were dissected and treated, for 5 min, with trypsin/
DMEM/EDTA medium (BioWhittaker, Cambrex, Belgium).
The treatment was stopped using complete DMEM plus 10%
FBS, and the cells were mechanically dissociated. After
mechanical dissociation, the debris was eliminated by filtration
(40 m, Falcon), and the cells were seeded (at a density of
60,000 cells/ml) in Neurobasal medium plus B27 supplemental
(containing glutamine, 1% penicillin/streptomycin and genta-
mycin) on poly-D-lysine (Sigma)-treated Nunc 12- or 96-well
plates. The cells were cultured at 37 °C, in humidified 5% CO2,
95% atmosphere.Mediumwas half-replaced every 4 days. After
13–15 days in culture, the cultures were treated with different
concentrations (ranging from 0.01 to 2 M) of ADDLs (pre-
pared as described above) or different concentrations (ranging
from0.27 to 54 nM) of sAPP. The cells were then incubated for
30 min and rinsed with cold PBS, and the proteins were
extracted as above. The neuronal survival was assayed using
MTS (Promega) following the manufacturer’s indications.
Statistical Analysis—Data were expressed as means  S.D.
The comparison between two mouse groups (WT and
PS1APP tg mice) was done by two-tailed t test. For compari-
son between several age groups, we used one-way analysis of
variance followed by Tukey post hocmultiple comparisons test
(Statgraphics plus 3.1). The significance was set at 95% of
confidence.
RESULTS
Age-dependent Modifications on the GSK-3 Activity in
PS1APP Mouse Hippocampus—The GSK-3 activity could
play a central role controlling apoptosis and the development of
Alzheimer disease. Because GSK-3 activity was inhibited by
phosphorylation on Ser-9, we have first quantified, byWestern
blots, the Ser-9 phospho-GSK-3 levels in our PS1APP tg
model.Weused twodifferent ages, 6 and 18months, before and
after pyramidal neurodegeneration, respectively (26, 30).West-
ern blot analysis demonstrated the existence of a clear age-de-
pendent variation of the Ser-9 phosphorylation levels in
PS1APP mice (Fig. 1A, panels a1 and a2). As compared with
6-month-old WT mice, the levels of Ser-9 phospho-GSK-3
were elevated in young PS1APP hippocampus, whereas the
18-month-old PS1APPmice displayed a significant decrease.
In fact, the Ser-9 phosphorylation level, at 18 months, repre-
sented a decrease of 5.66  0.46 times over 6-month-old
PS1APP mice. This observation was also confirmed using
immunohistochemistry. As shown in Fig. 1B, the phospho-
Ser-9 GSK-3 immunoreactivity was mainly located in the
somata of hippocampal neuronal cells. As also shown (Fig. 1B,
panels b1 and b2), a marked increase in the immunoreactivity
was observed in the hippocampus of 6-month-old PS1APP tg
mice, as compared withWT. This increase was evident in both
pyramidal and interneuronal cell somata and their proximal
dendrites. In parallel experiments, GSK-3 phosphorylation
immunostaining was clearly decreased in aged PS1APP tg
mice (Fig. 1B, panels b3 and b4).
The GSK-3 activity could modulate the intrinsic apoptotic
pathway by modifying, directly and/or indirectly, the expres-
sion of pro- and anti-apoptotic Bcl-2 family proteins (35–37).
Thus, we have determined the possible variations in the expres-
sion of mRNAs coding for Bcl-2 proteins in 6- and 18-month-
old WT and PS1APP tg mice. According to the phosphory-
lation of the GSK-3 (38), in 6-month-old PS1APP mice the
expression of bcl-2 was increased (Fig. 1C). On the contrary, in
18- month-old PS1APP animals, the expression of bcl-2 was
not different from WT, whereas bim and bad expression
increased exclusively in transgenic animals. These data could
indirectly reflect the activation of GSK-3 in aged PS1APP
mice. Additionally, the possible age-dependent activation of
the GSK-3 was also tested by determining the protein level
and phosphorylation status of -catenin (39). Although the
phosphorylated versus total -catenin ratio was not altered in
6-month-old PS1APP mice (Fig. 1D), we did observed an
increase in the steady-state levels of both -catenin forms.
These data were consistent with a reduced GSK-3 activity.
More relevant and also consistent with the proposed age-de-
pendent increase in the GSK-3 activity, the total and phos-
phorylated -catenin contents were dramatically reduced in
18-month-old PS1APPmice (Fig. 1D). Furthermore, the ratio
of phospho/total-catenin displayed a considerable increase in
these aged PS1APPmice, suggesting a hyperphosphorylation
status of the -catenin.
These data demonstrated the existence of an age-dependent
change in the phosphorylation of the GSK-3 in our PS1APP
tg model. Whereas at early ages the GSK-3 seemed to be
AOligomers Reverse Neuroprotective Effect of sAPP
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inhibited by Ser-9 phosphorylation (probably exerting a neuro-
protective action), in aged PS1APP mice the activation of
GSK-3 was increased.
Young and Aged PS1APP Hippocampus-derived Soluble
Factors Increased or Inhibited, Respectively, the Akt-dependent
Phosphorylation of GSK-3—We next investigated the possi-
bility that soluble APP-derived factors were involved in the
modulation of GSK-3 phosphorylation in both young (6
months) and aged (18 months) PS1APPmice. In this sense, it
has been recently reported thatmonomeric A42mediated the
activation of the PI3K-Akt pathway (40), whereas A oligomers
(ADDLs) induced an impairment of insulin receptors (27).
We have first determined in vitro using N2a cell cultures the
effect of soluble brain extracts, derived from 6- and 18-month-
oldWT, PS1 (data not shown), andPS1APPmice on the Ser-9
phosphorylation of GSK-3. As shown (Fig. 2A, and quantita-
tively in Fig. 2C), the addition of the soluble fractions obtained
from 6-month-old PS1APP mice produced a clear induction
in the GSK-3 phosphorylation over basal values (serum dep-
rivation). This increase was mediated by the activation of the
PI3K/Akt pathway because Akt was phosphorylated at both
Thr-308 and Ser-473 residues (Fig. 2A), and the effect was abol-
ished by the addition of LY294002 (data not shown). This acti-
vation of the PI3K/Akt pathway seemed to be mediated by at
FIGURE 1. Age-dependent decrease on GSK-3 phosphorylation (Ser-9) in PS1APP hippocampus. A, relative phosphorylation levels of Ser-9 GSK-3
(panel a1, upper panel) were determined, byWestern blots, in 6- and 18-month-oldWT and PS1APP hippocampi. TheWestern blots were then reprobed for
total GSK-3 (a1, lower panel). In these experiments, 10g of proteins fromWT and PS1APPmice were electrophoresed in parallel, using different distribu-
tions. In each gel, a minimum of three WT and three PS1APP samples were run together. The experiment was repeated three times using different sample
combinations. Quantitative analysis of the Western blots is shown in panel a2. The Western blots were scanned, and the ratio between phosphorylated/total
expression was calculated. In each experiment, the phosphorylation/total ratio was normalized by 6-month-old WT value. The total protein loading was also
tested by anti--actin antibody (data not shown). B, hippocampal (CA1) light microscopy images of phospho-Ser-9-GSK-3 immunohistochemistry from 6-
(panels b1 and b2) and 18-month-old (panels b3 and b4) WT (panels b1 and b3) and PS1APP (panels b2 and b4) mice. For these experiments, serial sections of
6- and 18 month-old WT and PS1APP brains were processed in parallel. Thus, both WT and PS1APP slices were equally developed. The image shown is
representative of four differentWT and PS1APPmice. Insets showhighermagnifications of stratumpyramidale.C, expression of different bcl-2 family protein
mRNAs was analyzed by quantitative RT-PCR. In each case, the results (n 7) were corrected by the GAPDH expression and normalized by 6-month-old WT
mice.D, total and phosphorylated-catenin levels were assessed byWestern blots (panel d1). Quantitative data are shown in panel d2. As shown, the total and
phosphorylated-catenin increased in samples from 6-month-old PS1APP, and there was a dramatic decrease in both levels in samples from 18-month-old
PS1APP mice. Furthermore, the phosphorylated/total ratio also increased at this old age. Significance difference between the different samples was deter-
mined by analysis of variance followed by Tukey test. so, stratum oriens; sp, stratum pyramidale. Scale bars, 50 m.
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least the IGF-1 and/or insulin receptors. In fact, both receptors
were activated (Tyr-phosphorylated) in the presence of these
soluble extracts. The activation of the Akt and phosphorylation
of GSK-3 were specific for the factors present in PS1APP
mice because the addition of a similar amount of soluble pro-
teins from WT or PS1 transgenic mice (data not shown) was
devoid of any effect.
In parallel experiments, we have also tested the effect of sol-
uble extracts from 18-month-old PS1APPmice (Fig. 2,A and
C). In contrast to that observed using young PS1APP,
18-month-derived soluble fraction did not induce the phos-
phorylation ofAkt-GSK-3 in serum-deprived cultures. In fact,
a small inhibition, over control values, was observed (Fig. 2C).
The soluble extracts from18-month-oldWTmice displayed no
intrinsic effect.
The possible inhibitory action of the soluble fractions from
aged transgenic mice was tested by analyzing their effect on the
serum-stimulated Akt-GSK-3 phosphorylation. As shown
(Fig. 2B), the treatment of N2a cells with fractions derived from
18-month-old PS1APPmice produced a practically complete
inhibition of the serum-induced GSK-3 phosphorylation (see
also Fig. 2C). This inhibition was paralleled by a decrease in
Akt473 and Akt308 phosphorylation and was also paralleled by
a decrease in the Tyr phosphorylation of IGF-1R and insulin
receptor. The soluble fractions from agedWT or PS1 (data not
shown) mice showed no apparent effect.
In addition, we have also examined the effect of 6- and
18-month-derived soluble fractions on neuronal survival
assays. For these experiments, primary neurons were subjected
to deprivation and supplemented with 6- or 18-month soluble
fractions. As expected (see supplemental Fig. 1), the soluble
extract from 6-month-old PS1APP avoided the decrease in
neuronal survival due to growth factor deprivation. As also
expected, the soluble fraction from 18 months did not protect
or even produce a small decrease on the neuronal survival. In
this sense, we also tested the possible neurotoxic effect of these
18-month PS1APP-soluble fractions. After 24 h of incuba-
tion, in the presence of B27 supplement, these soluble fractions
produced a significant decrease in the neuronal survival
(100.0 7.7% versus 80.19 2.6%, n 3; p 0.05). The WT-
derived soluble fractions displayed no intrinsic effect. These
data demonstrated that soluble factors present exclusively in
PS1APP-derived brain fractions modulated (positively or
negatively) theGSK-3 phosphorylation and neuronal survival.
Characterization of APP-derived Fragments from Young and
Aged PS1APPMice—Asmentioned above, APP-derived pro-
teins could modulate the GSK-3 phosphorylation. In conse-
quence, we have next analyzed, byWestern blots using themAb
6E10 (Fig. 3A), the presence of APP-derived soluble fragments
in these fractions. As shown, the soluble fractions from
6-month-old PS1APP mice exhibited a single specific (as
compared with WT) band of high apparent molecular weight
FIGURE2.Soluble fractions, derived from6-or 18-month-oldPS1APPmice, produced the stimulationor inhibitionofAkt-GSK-3phosphorylation.
A,N2a cultures were serum-deprived for 12 h and treated with 50g of soluble proteins derived from young (6months) or old (18months) WT and PS1APP
mice. After treatment, the phosphorylation levels of GSK-3 (Ser-9), Akt (Ser-473 or Thr-308), IGF-1R (phospho-Tyr-1135/1136), or IR (phospho-Tyr-1150/1151)
were determined by Western blots. As shown, the S1 fractions from 6-month-old PS1APP produced a clear induction of the phosphorylation levels of all
protein tested. B, possible inhibitory effect of 18-month-old PS1APP S1 fractions (50g of protein) was assessed in serum-stimulated Akt-GSK-3 pathways.
For each condition, two culture wells were treated in parallel, and the experiments were repeated at least three times. C, quantitative analysis of experiments
shown inA and B. The results aremean S.D. of three independent experiments. Datawere normalized by negative controls (C). Negative (C) and positive
(C) controls represented control experiments in the absence (12 h) or presence of serum, respectively. The protein loading was tested by total GSK-3 and
-actin.
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(Fig. 3A). Interestingly, no monomeric A was detected by this
assay, even after longer exposures (data not shown). Because
mAb 6E10 recognized both A peptides and sAPP, we
retested the Western blots using an anti-sAPP antibody. As
shown (Fig. 3B), a band of similar relative molecular weight
(Mr) was also observed with this antibody. Therefore, sAPP
was the predominant APP-derived fragment (detected with
6E10) in young PS1APP mouse hippocampi.
However, the analysis of the soluble fractions from
18-month-old PS1APPmouse hippocampi demonstrated the
presence of several oligomeric A forms. Based on the calcu-
lated Mr (24, 50, and 60–70 kDa), these A oligomers were
compatible with the presence of 6- and 12–16-mer, SDS-resis-
tant aggregates. As expected, these oligomers were immunopo-
sitive for A11 and Nu-1 antibodies in dot blots (data not shown
but see Ref. 26). It is also interesting the absence of monomeric
A in these fractions. It is of note that the presence of a rela-
tively abundant band localized in the high molecular weight
range. This band probably corresponded to a different highly
aggregated A oligomer because, as probed by Western blots
using anti-sAPP antibody, this soluble fragment did not
increase in aged PS1APP mice (see Fig. 2B).
To further characterize theseA oligomers, we used the con-
formation-dependent anti-oligomeric A11 antibody in immu-
noprecipitation assays. As shown (Fig. 3C), three different high
molecular weight A oligomers (50, 60–70, and 90–100 kDa)
were immunoprecipitated by A11 antibody. The 24-kDa olig-
omer was occluded by the presence of a prominent band corre-
sponding to the protein G-Sepharose. This putative 6-mer
oligomerwas clearly visualized usingA11-proteinA-Sepharose
immunocomplexes (data not shown but see below). Further-
more, as expected, A11 antibody did not immunoprecipitate
the sAPP (Fig. 3C).
To better resolve these relatively high molecular weight A
oligomers, the A11-immunoprecipitated proteins were also
analyzed in 12% Tris glycine gels (Fig. 3D). As shown, at least
five different putative A oligomers (detected by 6E10) of 24,
47, 57, 90, and 96 kDa were identified in these experiments. As
also shown, the sAPP (110-kDa band), present in the soluble
fraction, was not immunoprecipitated by A11. Therefore, the
aggregated forms presented in the soluble fractions from
18-month-old PS1APP mice were compatible with the pres-
ence of A oligomers of 6-, 10-, 12-, 20- and 22-mers.
Opposite Actions of Synthetic sAPP (Stimulation) and
ADDLs (Inhibition) on the Akt Prosurvival Pathway—Based on
the observed soluble fraction composition, we next character-
ized the effect of synthetic sAPP and A oligomers on the
Akt-GSK-3 phosphorylation (Fig. 4) using N2a cell cultures.
The soluble APP (Fig. 4A, panel a1, and quantitatively in
panel a2) produced a dose-dependent increase in the phos-
phorylation levels of Ser-9 GSK-3 and Akt (at Thr-308 and
Ser-473 residues), whereas the soluble APP, probed in parallel
experiments, produced no effect in this in vitro phosphoryla-
tion assay (Fig. 4A, panel a2). Interestingly, the sAPP dis-
played a quite high potency in the low nanomolar range
(EC50  2.30  0.93 nM, n  4; Fig. 4A, panel a2) coincident
with the estimated concentration (byWestern blots using com-
mercial sAPP as standard) of the sAPP in the soluble fraction
of the 6-month-old PS1APPmice (19.9 4.11 nM). This stim-
ulatory effectwas also replicated using primary cortical cultures
(supplemental Fig. 3A). As expected, sAPP seemed to exert its
effect acting through IGF-1R and insulin receptor (see Fig. 4A,
panel a1) and, in consequence, was inhibited by LY294002,
AG1024, and picropodophyllin (supplemental Fig. 2A).
These data indicated that in this in vitro model the sAPP
behaved like an agonist, acting at least through IGF-1R and
insulin receptors, activating the PI3K/Akt pathway and, in con-
sequence, phosphorylating and inhibiting the GSK-3 activity.
FIGURE 3. A oligomeric forms in soluble extracts from 18-month
PS1APP. A, S1 fractions from 6 month-old WT and PS1APP or 18-month
PS1APP were first analyzed by Western blot (16% SDS-Tris-Tricine-PAGE)
usingmAb 6E10. Results showed an age-dependent increase of soluble SDS-
resistant oligomeric species of approximately 24, 50, 60, and 90 kDa in
PS1APP animals. No significant amounts of mono-, di-, or trimers were
detected under these experimental conditions. B, Western blots (WB) were
re-tested using anti-sAPP antibody. Only a high molecular weight specific
band (90 kDa) was observed. No significant (NS) age-dependent changes
could be appreciated in this band. C, immunoprecipitation (I.P.) experiments
using A11 antibody were addressed for selective recognition of the A oli-
gomers in 18-month PS1APP-soluble extracts. The S1 fractions obtained
from18-month-oldWTor PS1APPwere incubatedwith A11-proteinG-Sep-
harose immunocomplexes and analyzed by 16% SDS-Tris-Tricine-PAGE and
Western blots using 6E10. As shown, the pattern of immunoisolated A oli-
gomers was similar to that observed in the crude S1 fraction. Anti-sAPP
antibody displayed no specific staining in these immunoprecipitated sam-
ples. D, A11 immunoisolated oligomers were resolved using 12%-SDS-Tris
glycine-PAGE and blotted as in C. Using this approach, at least five different
A oligomeric forms were identified. Western blots are representative of at
least four replicated experiments with similar results.
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In addition, saturating concentrations of sAPPpromotedneu-
ronal survival in a deprivation assay (supplemental Fig. 2B).
Aiming to test the possible inhibitory effect of oligomericA,
we have used synthetic A oligomers (ADDLs) (41). Similar to
natural A oligomers, the synthetic ADDLs displayed no
intrinsic effect in the absence of serum (data not shown). Also
similar to natural oligomers, in the presence of serum, ADDLs
displayed a dose-dependent inhibition of the GSK-3 phos-
phorylation (Fig. 4B, panel b1) with a calculated IC50 of 0.21
0.10 M (n 4) (Fig. 4B, panel b2). As expected from our pre-
vious data, this inhibitory effect was paralleled by an inhibition
of the serum-stimulated Akt activation (pAkt473 and -308)
(Fig. 4B, panel b1). This inhibitory effect was also replicated in
primary neuronal cultures (supplemental Fig. 3B).
In addition, we have tested the possible neuroprotective
effect of sAPP and 6-month PS1APP-soluble fractions on
ADDL (2 M) toxicity (supplemental Fig. 3C). As shown, the
sAPP and 6-month PS1APP soluble fractions avoided (par-
tially and fully, respectively) the ADDL-induced neuronal
toxicity.
Based on these observations, we postulated that if the stim-
ulation (at 6 months) or inhibition (18 months) of the Akt-
FIGURE 4. Synthetic sAPP andAoligomers (ADDLs) stimulatedor inhibited theAkt-GSK-3phosphorylation inN2a cultures.A, sAPP activated the
IGF-1R/IR Akt GSK-3 pathway. Serum-deprived N2a cultures were treated with increasing concentrations of synthetic sAPP or sAPP (data not shown), and
the phosphorylations of Ser-9 GSK-3, Akt (473 and 308), IGF-1R (Tyr-1135/1136), and IR (Tyr-1150/1151) were analyzed byWestern blots (panel a1). Panel a2,
quantitative analysis ofWesternblots normalizedbynegative control (C).B, inhibitory effect of increased concentrations of ADDLs onAkt-GSK-3phosphor-
ylation was assessed in N2a maintained in the presence of serum. Western blots (panel b1) and quantitative analysis of the data (panel b2) are illustrated.
C, immunodepletion experiments. The S1 fractions, derived from6- (panel c1) or 18-month-old (panel c2) PS1APPmice,were immunodepleted using 6E10 or
A11, and the samples were tested for stimulation experiments (as above) in the absence (panel c1) or presence of serum (panel c2). Panel c3, quantitative
analysis of the Western blots. Data were normalized by the corresponding negative control and are means S.D. of three independent experiments. Data
(mean S.D.) presented in panels a2 and b2were fitted to a logistic four-parameter equation as described previously (34, 62). The protein loading was tested
by total GSK-3 and -actin.
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GSK-3 phosphorylation was indeed mediated by sAPP, at 6
months, or A oligomers, at 18 months, their effect should be
avoided by immunodepletion using 6E10 (for sAPP) or A11
(for A oligomers). Therefore, we tested the stimulation or
inhibition of Akt-GSK-3 phosphorylation after three sequen-
tial immunodepletions of the soluble fractions with either 6E10
(for 6 months) or A11 (18 months). The results are shown in
Fig. 4C (and quantitatively in Fig. 4C, panel c3). As expected,
after immunodepletionwith 6E10, the stimulatory action of the
6-month-derived fractions was completely avoided (Fig. 4C,
panel c1). Neither GSK-3 nor Akt 473/308 was phosphory-
lated after 6E10 immunodepletion. Conversely, the inhibitory
effect of the 18-month-derived fraction was completely
reversed by A11 immunodepletion (Fig. 4C, panel c2). As
shown, the serum-induced GSK-3 and Akt473/308 phos-
phorylation was almost completely re-established after A11
treatment.
Therefore, at young ages in our PS1APP model, the pro-
duction of sAPP determined the activation of Akt and the
phosphorylation of Ser-9-GSK-3 (throughout at least IGF-1
and/or insulin receptors), whereas the age-dependent appear-
ance of soluble oligomeric forms of A determined the inhibi-
tion of this pro-survival pathway.
Synthetic A Oligomers Inhibit the Activation of Prosurvival
Receptors—Because of the relevance of the inhibition of the
pro-survival pathways in the development of AD, we have fur-
ther evaluated the inhibitory properties of the oligomeric A
using in vitro assays. It has been suggested that A oligomers
could inhibit the prosurvival Akt-GSK-3 phosphorylation by
direct interaction with at least insulin receptors (42) and/or
produced insulin resistance (27, 43). To ascertain the possible
specificity in the ADDL inhibition, we determined the effect of
two different concentrations of ADDLs (0.2 and 2 M) on the
stimulatory effect of IGF-1, insulin, BDNF, NGF, and sAPP
(Fig. 5A, panels a1 and a2). As expected, the addition of the
different factors produced the phosphorylation of the GSK-3,
demonstrating the presence of functional receptors in the N2a
cells. As also shown in Fig. 5A, ADDLs inhibited the induced
GSK-3 phosphorylation for all factors tested. Importantly, the
effect of ADDLs displayed a clear selectivity on the inhibitory
action. As shown, the NGF stimulation of GSK-3 phosphory-
lation seemed to be preferentially inhibited. In fact, 0.2 M
ADDLs completely blocked the NGF stimulation. In contrast,
BDNF stimulation displayed low sensitivity to the ADDL effect.
Only a minor inhibition could be observed at the highest dose
used (2 M). Insulin, IGF-1. and sAPP presented intermedi-
ated sensitivity.
This selectivity could indicate that ADDLs might interact
directly with the different trophic receptors. Theoretically, if
both ligands exert their action through the same receptor, the
ADDL inhibition should be reverted by increasing the trophic
factor concentration. In fact, the inhibitory effect of submaxi-
mal doses of ADDLs (20 nM) was totally reverted by increasing
concentrations of NGF (Fig. 5B, panels b2 and b2). Similar
results were observed using IGF-1 or insulin (data not shown).
Based on these data, we cannot discriminate between a direct
inhibition or a negative allosteric effect of ADDLs. However,
these data indicated that the inhibitory action of A oligomers
was, at least in part, mediated by a direct interaction with dif-
ferent prosurvival receptors. In fact, ADDLs inhibited the Tyr
phosphorylation of IGF-1, insulin, and Trk-A receptors (sup-
plemental Fig. 4). The results indicated that for all three recep-
tors the addition of ADDLs prevented the Tyr phosphorylation
and, consequently, the receptor activation. This effect was par-
ticularly evident for IGF-1R. Therefore, the ADDLs seemed to
be acting primordially at the activation level of the different
receptors tested.
DISCUSSION
Multiple APP-based transgenic mouse models have been
developed to evaluate the neurological deficiencies observed in
AD. However, none of them displayed all pathological signs of
the disease. The most relevant discrepancies between AD and
the transgenic models were the absence of Tau phosphoryla-
tion and late, if any, neuronal degeneration, even in the pres-
ence of large A accumulation since early ages. This apparent
age-dependent neuroprotective/neurodegenerative status has
not yet been fully addressed. Here, using in vivo and in vitro
assays, we demonstrated the following. 1) sAPP acting
through IGF-1R and insulin receptors activated the prosurvival
PI3K-Akt-GSK-3 pathway, which might explain the lack of
neuronal death inmost transgenicmodels at early/middle ages.
2) The age-dependent increase in solubleA oligomers blocked
the neurotrophin (including sAPP)-mediated prosurvival
pathway, explaining the observed late neuronal vulnerability.
It has been postulated that GSK-3 activity might exert a
central role in the development of AD. GSK-3 activity was
implicated in Tau phosphorylation, APP processing, A pro-
duction, and neurodegeneration (15). Overexpression of
GSK-3 in a conditional transgenic model produced Tau
hyperphosphorylation and neuronal death (16, 44). Further-
more, pharmacological inhibition of the GSK-3 activity by
lithium decreased A production and plaque accumulation
(45), improved performance in memory tests, preserved the
dendritic structure, and reduced the Tau-dependent pathology
in AD tg models (46, 47).
Therefore, in this study we have first determined the Ser-9
phosphorylation levels in young/middle (6 months) and aged
(18 months) PS1APP mice, before and after pyramidal cell
neurodegeneration in hippocampus, respectively (26). Accord-
ingly, with a putative neuroprotective environment at early/
middle ages, young PS1APP mice displayed significantly
higher levels of neuronal GSK-3 Ser-9 phosphorylation, sug-
gesting a decreased activity of this enzyme. Also, we have
observed an increased expression of the anti-apoptotic Bcl-2
protein (38) and the increase in the -catenin protein. These
data could indicate the presence of increased levels of neurotro-
phins in this tg model. However, except for IGF-1, which was
locally increased around theA plaques (although its total con-
centration decreased in 6- and 18-month PS1APP mice,
results not shown), none of the growth factors analyzed were
modified in our transgenic model (data not shown). On the
contrary, we demonstrated that soluble fractions derived from
6-month-old PS1APP, and not fromWTor PS1, activated the
IGF-1R/IR-Akt pathway, phosphorylated the GSK-3, and in
AOligomers Reverse Neuroprotective Effect of sAPP
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consequence, promoted the neuronal survival in primary
cultures.
Within the different APP-derived fragments, both soluble
APP and - (data not shown) were the predominant APP pep-
tides identified in the tg-soluble fractions. Although the mono-
meric A could also produce a similar effect (data not shown)
(40), no significant amounts ofmonomeric Awere detected in
6-month-derived soluble extracts.
The implication of sAPP in the activation of the Akt pro-
survival pathway was further demonstrated in vitro, using syn-
thetic sAPP. The sAPP produced a dose-dependent activa-
tion of the Akt-GSK-3 pathway that was inhibited by
LY294002, AG1024, and picropodophyllin andmediated by the
activation of, in this in vitro assay, IGF-1 and insulin receptors.
Moreover, the effect of 6-month-old PS1APP brain-derived
fractions was completely avoided by immunodepletion experi-
ments using 6E10. Furthermore, the estimated sAPP concen-
tration in the soluble fractions (20 nM) was in the range of the
calculated EC50 for synthetic sAPP (2.3 nM). Interestingly, the
sAPP fragment displayed no intrinsic activity in this in vitro
model. To the best of our knowledge, this is the first time that
the effect of sAPP on Akt-GSK-3 pathway has been directly
demonstrated.
The present data cannot demonstrate, in vivo, a direct cause-
effect relationship between the presence of sAPP andGSK-3
phosphorylation. However, we might postulate that, in our
model, the overexpression of the tg APP produced increased
amounts of sAPP and, because of its agonist-like effect on the
prosurvival receptors, could to some extent delay the A
pathology. In fact, although the increase in GSK-3 phosphor-
ylation was not observed in all APP-based tgmodels (48, 49), all
models exhibited a considerable delay between the A deposi-
FIGURE 5. Synthetic A oligomers (ADDLs) competed with different neurotrophins for the stimulation of Ser-9 GSK-3 phosphorylation. A, for
competition experiments, the Ser-9 GSK-3 phosphorylation was stimulated by a fixed concentration of different neurotrophins and 0.2 or 2M ADDLs. After
treatment, the Ser-9 GSK-3 phosphorylation was determined by Western blots (panel a1) and quantitatively (panel a2) after normalization by negative
controls.B, inhibitory effect of ADDLs, at submaximal doses (20nM)was revertedby increasing the concentrationof different neurotrophins, such asNGF, IGF-1
or insulin. In these experiments, N2a cells were treatedwith different concentrations of each neurotrophin in the absence (data not shown) or presence (panel
b1) of ADDLs. After Western blots, the GSK-3 phosphorylation was quantitatively analyzed (panel b2) and normalized by negative controls. C, negative
control; C, positive control.
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tion and the appearance of neuronal pathology (if any). Thus,
data presented in this work add a new connection betweenAPP
metabolism andGSK-3 regulation that could explain the slow
pathological progression, observed in all transgenic models,
and also the decrease in tauopathy6 and increased survival of
somebigenicAPP-Taumodels (50).Moreover, the activation of
the-secretase activity, with a parallel increase in sAPP secre-
tion, could constitute a novel therapeutic approach in AD (51).
In addition, we have also demonstrated the inhibitory effect
of natural oligomeric forms of A on theAkt-GSK-3 pathway.
It should be noted the presence of five different soluble, SDS-
resistant A oligomers of 24, 47, 57, 90, and 96 kDa in the
18-month PS1APP brain-derived fractions. The identity of
these A oligomeric peptides was confirmed using the poly-
clonal anti-oligomeric antibody A11 in immunoprecipitation
experiments, followed by Western blots using 6E10. These
results confirmed our previous data using this tg model (26 and
also see Refs. 20, 23).
We observed a clear inhibition of Akt phosphorylation when
N2a cells were treated with soluble fractions derived from
18-month-old PS1APP tg mice (see also Ref. 52). This inhibi-
tion seemed to be mediated by a direct effect on trophic recep-
tors because activation (Tyr phosphorylation) of at least IGF-1
and insulin receptors was inhibited by the addition of these
soluble fractions. Furthermore, this inhibitory effect was exclu-
sively due to the presence of A oligomers, because the immu-
nodepletion of A oligomers, using A11, completely reversed
the inhibitory effect. Thus, the age-dependent appearance of
extracellular A oligomers could inhibit the Akt-GSK-3 pro-
survival pathway. This inhibitory effect was consistent with the
age-dependent decrease in the Ser-9-GSK-3 phosphorylation,
the increase in phosphorylatedTau (results not shown), and the
-catenin hyperphosphorylation and degradation observed in
hippocampal samples from 18-month-old PS1APP mice. In
addition, as we recently reported, the presence of extracellular
A oligomers determined the potential cytotoxic microglial
activation, coincidentally with CA1 pyramidal cell loss (26).
Those data, together with the present observations, demon-
strated that accumulation of extracellular A oligomers deter-
mined the inhibition of the prosurvival pathways coincidentally
with the activation of a potentially cytotoxic inflammatory
response. Both actions could indeed create the appropriate
environment to induce the observed neuronal death.
Our data also indicated that ADDLs could exert their inhib-
itory action by a direct effect on the different trophic receptors.
This assessment was based on the following: (i) the higher
ADDL selectivity for NGF than for BDNF, and (ii) the reversion
of the inhibitory effect by increasing concentrations of the neu-
rotrophin (NGF, insulin, or IGF-1). A possible direct effect of
A oligomers and IR has been also suggested previously (27,
42). However, we cannot discard that ADDLs might also exert
an inhibitory action by a different mechanism. In this sense, it
has been suggested that ADDLs, acting on other different
receptors such as N-methyl-D-aspartic acid or p75NTR (53–
55), could reduce or even inhibit the insulin response (27, 43)
through Akt473 phosphorylation with no activation of the
pathway. However, in our in vitro system, the phosphorylation
of Akt473 always paralleled Akt308 and GSK-3 Ser-9, even
using primary neuronal cultures (data not shown). We do not
know the origin of this disagreement; however, in our in vitro
assays, the cells were incubated with ADDLs for a short time
(20–30 min) in order to minimize the possible cellular death.
Thus, it is possible that longer ADDL treatment was required.
Concerning the possible physiological relevance of our
observations, it should be mentioned that chronic decrease in
the trophic signaling, such as NGF, could be implicated in AD
development (7, 56, 57). In this sense, the selective inhibitory
effect of A oligomers (NGF 	 IGF-1  insulin 	 BDNF)
might contribute to this decreased signal and, in consequence,
be implicated in the preferential vulnerability of the cholinergic
system observed in AD. It has also been demonstrated that A
oligomers could directly bind to p75NTR (55, 58) producing the
formation of neuritic dystrophies (also observed in our model)
(30, 59, 60) and the activation of c-Jun kinases mediating cell
degeneration (61). Thus, the appearance of A oligomers could
actively decrease the trophic support, interacting with trophic
receptors (this work), and/or increase the toxic signaling acti-
vating death receptors such as p75NTR.
In summary, our data demonstrated that the presence of sol-
uble factors in PS1APP mice modulated the GSK-3 Ser-9
phosphorylation. In young tg mice, sAPP, acting at least
through IGF-1R and IR, determined the activation of Akt-
GSK-3 phosphorylation pathway. The activation of this path-
way, classically assigned as pro-survival, could influence the
limited Tau phosphorylation and neuronal degeneration
observed in most tg models. At relatively late ages (18
months), the presence of multiple A oligomeric forms
determined the inhibition of the signal of all neurotrophins
tested. The effect of A oligomers might be mediated by
interaction with the different receptors, although a different
and more complex action cannot be discarded. This in vitro
inhibition of the prosurvival signal was also supported with
in vivo data, demonstrating a decrease in GSK-3 Ser-9
phosphorylation and an increase in AT100 immunoreactiv-
ity. Revealing the prosurvival pathways used by the different
vulnerable neuronal subsets will provide further insights
into the molecular mechanisms of AD pathogenesis.
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Supplemental Figure 1. Soluble fractions from 6 months PS1xAPP mice promoted the neuronal 
survival after deprivation. Primary neuronal cultures were incubated, for 24h, in: Neurobasal 
medium in presence (C+), in absence (C-) of B27 supplement; or in presence of soluble 
fractions (50 μg of protein) derived from 6- and 18-month-old WT and PS1xAPP mice. After 
treatment, the neuronal survival was tested by MTS assay (as recommended by the 
manufacturer). The experiment was done in triplicate and repeated twice. Significance 
difference between the different samples was determined by ANOVA followed by Tukey test   
 
  
Supplemental Figure 2. A) sAPPalpha mediated GSK-3β phosphorylation was inhibited by 
PI3K and IGF-1R or IR inhibitors. Before stimulation, serum deprived N2a cell cultures were 
pre-treated (30 min) with 10μM Ly294002, 100 nM AG1024 or 500nM PPP and then 
stimulated with sAPPalpha as described. For these experiments, duplicate wells were treated in 
parallel with different inhibitors. These experiments were repeated twice with similar results. 
B) Soluble APPalpha promoted the primary neuronal survival. Primary neuronal cultures were 
incubated, for 24h, in: Neurobasal medium in presence (C+), in absence (C-) of B27 
supplement; or in presence of 27nM and 54nM sAPPalpha. After treatment, the neuronal 
survival was tested by MTS assay. The experiment was done in triplicate and repeated twice. 
Significant differences were analyzed as in supplemental Fig.1 
 
 
 
Supplemental Figure 3. The sAPPα and ADDL mediated opposite actions on GSK-3beta Ser9 
phosphorylation and in ADDLs toxicity in neuronal primary cultures. A) The neuronal cultures 
were deprived (3 h) of B27 supplement (C-) and incubated for 30 min with: B27 (C+) or 
increasing concentrations of sAPPalpha (indicated in the Figure). B) The neuronal cultures were 
incubated (30 min) with different concentration (ranging from 0.01 to 2µM) of ADDLs. C) 
Neuronal toxicity was induced by the addition of saturating concentration (5 μM) of ADDL in 
presence of B27 or 54nM sAPPalpha. Additionally, in the same experiment we also assessed the 
protective effect of 50 μg 6-month PS1xAPP soluble fraction. The experiment was done in 
triplicate cultures. Significant differences were analyzed as in supplemental Fig.1 
 
 
Supplemental Figure 4.  ADDLs inhibition of IGF-1R, IR or TRK-A phosphorylation.  For this 
analysis, the protein extracts described in Fig.5 were used and the Tyr phosphorylation of 
different receptors were analyzed by western blots. Westerns were representative of three 
different experiments. Note the high levels of TRK-A background due to the low expression of 
this receptor in N2a cells and the relative high amount of proteins (30 μg) needed for these 
particular western blots.  
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